<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药融圈 | wechat-feeds</title><link>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</link><description>药融圈PHARNEX汇聚数万医药大咖，得到数千家医药创业者鼎力支持，开展日常专题讲座。致力于成为“专业、前沿、权威、严谨”的医药行业资讯平台，以及项目、技术、工厂、融资、股权投资等资源整合平台。欢迎您关注药融圈，共同碰撞“药”的火花!</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 08 Feb 2021 11:37:16 +0800</pubDate><image><url>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</url><title>药融圈 | wechat-feeds</title><link>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>新春独家：跨国药企在华研发中心现在都在做什么？</title><link>https://mp.weixin.qq.com/s/0jPMS1mlo5Ur5ok3fezQ8A</link><description></description><content:encoded><![CDATA[新春独家：跨国药企在华研发中心现在都在做什么？]]></content:encoded><pubDate>Sun, 07 Feb 2021 23:33:42 +0800</pubDate></item><item><title>靶点药讯47|纵览全球药物靶点动态</title><link>https://mp.weixin.qq.com/s/l46EvRUeQXs2s2SPYotsbQ</link><description></description><content:encoded><![CDATA[靶点药讯47|纵览全球药物靶点动态]]></content:encoded><pubDate>Sun, 07 Feb 2021 23:33:42 +0800</pubDate></item><item><title>信达，再鼎之后，岸迈生物LAG-3/PD-1双抗EMB-02获批临床</title><link>https://mp.weixin.qq.com/s/jGR-uRNFDDlJfqAjlEplrQ</link><description></description><content:encoded><![CDATA[信达，再鼎之后，岸迈生物LAG-3/PD-1双抗EMB-02获批临床]]></content:encoded><pubDate>Sun, 07 Feb 2021 23:33:42 +0800</pubDate></item><item><title>阿斯利康durvalumab在头颈癌中未达标，中国死亡率达52%</title><link>https://mp.weixin.qq.com/s/c6lOF-inCexyTaJRS7vvWw</link><description></description><content:encoded><![CDATA[阿斯利康durvalumab在头颈癌中未达标，中国死亡率达52%]]></content:encoded><pubDate>Sun, 07 Feb 2021 23:33:42 +0800</pubDate></item><item><title>仅用 3 天！国内第2款新冠疫苗获批；第4批国采本周落幕；海思科新药环泊酚注射液新适应症获批</title><link>https://mp.weixin.qq.com/s/gLYiYU_c6cxhpHpoCCKT-A</link><description></description><content:encoded><![CDATA[仅用 3 天！国内第2款新冠疫苗获批；第4批国采本周落幕；海思科新药环泊酚注射液新适应症获批]]></content:encoded><pubDate>Sun, 07 Feb 2021 23:33:42 +0800</pubDate></item><item><title>速报 | 重磅PI3K抑制剂Umbralisib获FDA加速批准，边缘区和滤泡性淋巴瘤患者迎来福音</title><link>https://mp.weixin.qq.com/s/L7JDkQzVLWxgqX53P6Akxg</link><description></description><content:encoded><![CDATA[速报 | 重磅PI3K抑制剂Umbralisib获FDA加速批准，边缘区和滤泡性淋巴瘤患者迎来福音]]></content:encoded><pubDate>Sun, 07 Feb 2021 23:33:42 +0800</pubDate></item><item><title>Nature：uPAR CAR-T开创抗衰老细胞治疗</title><link>https://mp.weixin.qq.com/s/x0aljrUgjG4fSyUZGBehMw</link><description></description><content:encoded><![CDATA[Nature：uPAR CAR-T开创抗衰老细胞治疗]]></content:encoded><pubDate>Sun, 07 Feb 2021 23:33:42 +0800</pubDate></item><item><title>FIC :首款口服药物​Lupkynis®狼疮肾炎在美获批</title><link>https://mp.weixin.qq.com/s/FQOuAD3HpBNFdfauViSYGg</link><description></description><content:encoded><![CDATA[FIC :首款口服药物​Lupkynis®狼疮肾炎在美获批]]></content:encoded><pubDate>Sat, 06 Feb 2021 22:17:56 +0800</pubDate></item><item><title>新春预告：大湾区(广州)生物医药创新者峰会启动</title><link>https://mp.weixin.qq.com/s/7jILIMggF4FkmS-1N0vpRw</link><description></description><content:encoded><![CDATA[新春预告：大湾区(广州)生物医药创新者峰会启动]]></content:encoded><pubDate>Sat, 06 Feb 2021 22:17:56 +0800</pubDate></item><item><title>2020年中国对巴西药品出口大幅增长197%</title><link>https://mp.weixin.qq.com/s/JSpSctTdKz-FlUxZ26MJcg</link><description></description><content:encoded><![CDATA[2020年中国对巴西药品出口大幅增长197%]]></content:encoded><pubDate>Sat, 06 Feb 2021 22:17:56 +0800</pubDate></item><item><title>AI+新药研发平台英飞智药获得丽珠医药Pre-A轮投资</title><link>https://mp.weixin.qq.com/s/AyfDwbX28MMHDtFtOfLosg</link><description></description><content:encoded><![CDATA[AI+新药研发平台英飞智药获得丽珠医药Pre-A轮投资]]></content:encoded><pubDate>Sat, 06 Feb 2021 22:17:56 +0800</pubDate></item><item><title>BD交易|小野制药近1.5亿美元引进一款PARP7抑制剂部分权益</title><link>https://mp.weixin.qq.com/s/DAkClRbUHhWjj2w7z9RurQ</link><description></description><content:encoded><![CDATA[BD交易|小野制药近1.5亿美元引进一款PARP7抑制剂部分权益]]></content:encoded><pubDate>Sat, 06 Feb 2021 22:17:56 +0800</pubDate></item><item><title>重磅！中国药科大学、沈阳药科大学等入选！</title><link>https://mp.weixin.qq.com/s/5a83CFPh0mucP1MMWmI2Gw</link><description></description><content:encoded><![CDATA[重磅！中国药科大学、沈阳药科大学等入选！]]></content:encoded><pubDate>Sat, 06 Feb 2021 22:17:56 +0800</pubDate></item><item><title>海和药物提交科创板上市申请，拟募资31.5亿元</title><link>https://mp.weixin.qq.com/s/SOkDP_OrvToe8VM4c9977Q</link><description></description><content:encoded><![CDATA[海和药物提交科创板上市申请，拟募资31.5亿元]]></content:encoded><pubDate>Sat, 06 Feb 2021 22:17:56 +0800</pubDate></item><item><title>大分子CDMO全球劲敌：药明生物PK三星生物—2015到2020业绩对比</title><link>https://mp.weixin.qq.com/s/8n-4wpzUDix-fXZV7MVQ6g</link><description></description><content:encoded><![CDATA[大分子CDMO全球劲敌：药明生物PK三星生物—2015到2020业绩对比]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:50:04 +0800</pubDate></item><item><title>新春预告：大湾区(广州)生物医药创新者峰会启动</title><link>https://mp.weixin.qq.com/s/52ftpY9fW3FG28Lzayhw2g</link><description></description><content:encoded><![CDATA[新春预告：大湾区(广州)生物医药创新者峰会启动]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:50:04 +0800</pubDate></item><item><title>新航线：中国药企征战欧洲指南</title><link>https://mp.weixin.qq.com/s/aBrIP_Eo7bJPDjZ3uBhzxg</link><description></description><content:encoded><![CDATA[新航线：中国药企征战欧洲指南]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:50:04 +0800</pubDate></item><item><title>罗氏2020年报出炉，创新药销量大增</title><link>https://mp.weixin.qq.com/s/8b0UocSwPKVbQ3ORa9TTJg</link><description></description><content:encoded><![CDATA[罗氏2020年报出炉，创新药销量大增]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:50:04 +0800</pubDate></item><item><title>四环医药近四日股价大幅上涨超20%，市值达223.39亿港元！传统药企也能焕发另一春</title><link>https://mp.weixin.qq.com/s/6t7wP5rMoig_CbDhN2mc6A</link><description></description><content:encoded><![CDATA[四环医药近四日股价大幅上涨超20%，市值达223.39亿港元！传统药企也能焕发另一春]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:50:04 +0800</pubDate></item><item><title>氯胺酮可穿戴式疗法Bexson完成480万美元A轮融资</title><link>https://mp.weixin.qq.com/s/Lh2TMQ8kYwYFWAgs_hsDDg</link><description></description><content:encoded><![CDATA[氯胺酮可穿戴式疗法Bexson完成480万美元A轮融资]]></content:encoded><pubDate>Fri, 05 Feb 2021 16:50:04 +0800</pubDate></item></channel></rss>